Florian Falter

Senior Associate
Norton Rose Fulbright LLP
florian.falter@nortonrosefulbright.com
Florian
Falter
Florian Falter
Munich
Theatinerstrasse 11
Munich
Germany
+49 (89) 212148325

Florian Falter advises national and international companies on all kind of regulatory questions in the life sciences sector, including product classification, clinical trials, market access, reimbursement, advertisement and promotion, distribution, and post-market obligations. He further advises on life sciences regulatory matters in connection with domestic and cross-border M&A transactions related to pharma, medical device or other life sciences businesses.

Representative experience

  • Mallinckrodt on the regulatory aspects of the international carve-out sale of its Therakos business comprising medical device and pharmaceutical components to CVC Capital Partners.

  • Kühne Holding AG and E3X Partners GmbH on the acquisition of the pharmaceutical contract development and manufacturing organization (CDMO) Aenova Group from the private investment company BC Partners.

  • Organon on comprehensive regulatory questions on medicinal products and medical devices as well as on corresponding distribution channels, import, pharmacovigilance, and advertising.

  • Carl Zeiss Meditec in connection with a cloud-based digital health platform as well as the implementation of this health platform in an app.

  • A global pharmaceutical company on issues relating to the regulation of in vitro diagnostics, in particular the placement on the market of Laboratory Developed Tests (LDTs).

  • Vision HealthCare, a consumer healthcare company headquartered in Belgium with an extensive portfolio of self-care brands and over-the-counter products in several European countries, on the acquisition of 100% of the shares of AixSwiss BV, a leading provider of probiotic dietary supplements.

  • Enovis Corporation on an investment in the German digital health start-up Orthopy Health GmbH and the related regulatory questions on the reimbursement of digital health apps (DiGAs) in Germany.

  • Global pharmaceutical companies in patent litigation cases and related pharmaceutical law and regulatory questions.

  • Kyowa Kirin International (KKI) on its joint venture collaboration with global science-based, privately owned pharmaceutical company Grünenthal for KKI's established medicines portfolio.

Education

  • First German Law Degree, University of Passau
  • Second German Law Degree, Higher Regional Court of Nuremberg

Admissions

  • Rechtsanwalt (German qualified lawyer)

Languages

  • English
  • German
Bio